Sorbent Therapeutics Receives $6,500,000 Series D Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c9baf2f7-9a9c-46a5-a650-50614dacdce7 - Date
5/15/2014 - Company Name
Sorbent Therapeutics - Mailing Address
710 Lakeway Drive Sunnyvale, CA 94085 USA - Company Description
Sorbent Therapeutics is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), Congestive Heart Failure (CHF), Chronic Kidney Disease (CKD), and Hypertension. - Website
http://www.sorbentrx.com - Transaction Type
Venture Equity - Transaction Amount
$6,500,000 - Transaction Round
Series D - Proceeds Purposes
Proceeds from the financing will be used to support continued development of CLP-1001 and general corporate operations. Sorbent completed the enrollment of 275 patients with heart failure in its Phase 2b STEPWISE clinical trial of CLP-1001, a cross-linked polyelectrolyte polymer intended to selectively bind to and remove excess water and sodium in the GI tract. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
